Scarlet Therapeutics Ltd
Ash Toye is a Professor of Cell Biology and Director at the University of Bristol. They are also the Director of the NIHR Blood and Transplant Research Unit in Red Cell products. Additionally, they hold the position of NHS Blood and Transplant Principal Investigator and Reader in Cell Biology at the university. In 2022, Ash Toye co-founded Scarlet Therapeutics Ltd and currently serves as a Co-founder at the company. They obtained a Doctor of Philosophy (PhD) in Biochemistry from the University of Bristol in 1997, following a Bachelor of Science (BSc Hons) in Biochemistry in 1994.
This person is not in any teams
Scarlet Therapeutics Ltd
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many unique qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.